Targeted RAS Drug Shows Survival Benefit Across Advanced Pancreatic Cancer Subgroups
A subgroup analysis of the phase 3 RASolute 302 trial presented at ESMO found the targeted RAS inhibitor daraxonrasib extended ...
Tag: RASolute 302
POPULAR NEWS
-
Blade Attachment Boosts Rowing Propulsion by Reshaping Leading-Edge Vortices
-
Targeted RAS Drug Shows Survival Benefit Across Advanced Pancreatic Cancer Subgroups
-
Risk-Averse Optimization Model Maps Cost, Carbon and Financial Risk in Thailand’s Biomass Pellet Supply Chain
-
Rare primitive neuroectodermal tumor of the uterus diagnosed through molecular exclusion